Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies

Coley, 1893, The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases, Clin Orthop Relat Res, 1991, 3 Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012 Dunn, 2002, Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, 3, 991, 10.1038/ni1102-991 Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Canc, 12, 252, 10.1038/nrc3239 Iwai, 2005, PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells, Int Immunol, 17, 133, 10.1093/intimm/dxh194 Leach, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, 271, 1734, 10.1126/science.271.5256.1734 Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci U S A, 107, 4275, 10.1073/pnas.0915174107 Shi, 2016, Interdependent IL-7 and IFN-gamma signalling in T-cell controls tumour eradication by combined alpha-CTLA-4+alpha-PD-1 therapy, Nat Commun, 7, 12335, 10.1038/ncomms12335 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 364, 2517, 10.1056/NEJMoa1104621 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030 Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, 8, 793, 10.1038/nm730 Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, 192, 1027, 10.1084/jem.192.7.1027 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Taube, 2014, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res, 20, 5064, 10.1158/1078-0432.CCR-13-3271 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Aguiar, 2017, PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data, Immunotherapy, 9, 499, 10.2217/imt-2016-0150 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Passiglia, 2016, PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis, Oncotarget, 7, 19738, 10.18632/oncotarget.7582 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N Engl J Med, 372, 2006, 10.1056/NEJMoa1414428 Carbone, 2017, First-line nivolumab in stage IV or recurrent non-small-cell lung cancer, N Engl J Med, 376, 2415, 10.1056/NEJMoa1613493 Kluger, 2015, Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites, Clin Cancer Res, 21, 3052, 10.1158/1078-0432.CCR-14-3073 Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, 4, 127ra137, 10.1126/scitranslmed.3003689 Sunshine, 2017, PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison, Clin Cancer Res, 23, 4938, 10.1158/1078-0432.CCR-16-1821 Clark, 2016, Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma, Cancer Res, 76, 6964, 10.1158/0008-5472.CAN-16-0258 Chang, 2013, Posttranscriptional control of T cell effector function by aerobic glycolysis, Cell, 153, 1239, 10.1016/j.cell.2013.05.016 Chen, 2016, Regulation of PD-L1: a novel role of pro-survival signalling in cancer, Ann Oncol, 27, 409, 10.1093/annonc/mdv615 Seidel, 2018, Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations, Front Oncol, 8, 86, 10.3389/fonc.2018.00086 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 Jacquelot, 2017, Predictors of responses to immune checkpoint blockade in advanced melanoma, Nat Commun, 8, 592, 10.1038/s41467-017-00608-2 Rimm, 2017, A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer, JAMA Oncol, 3, 1051, 10.1001/jamaoncol.2017.0013 Schmid, 2018, Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, N Engl J Med, 379, 2108, 10.1056/NEJMoa1809615 Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369 Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 Van Allen, 2015, Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, 350, 207, 10.1126/science.aad0095 Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Spranger, 2015, Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity, Nature, 523, 231, 10.1038/nature14404 Fridman, 2017, The immune contexture in cancer prognosis and treatment, Nat Rev Clin Oncol, 14, 717, 10.1038/nrclinonc.2017.101 Dighe, 1994, Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors, Immunity, 1, 447, 10.1016/1074-7613(94)90087-6 Kaplan, 1998, Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice, Proc Natl Acad Sci U S A, 95, 7556, 10.1073/pnas.95.13.7556 Ikeda, 2002, The roles of IFN gamma in protection against tumor development and cancer immunoediting, Cytokine Growth Factor Rev, 13, 95, 10.1016/S1359-6101(01)00038-7 Gao, 2016, Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy, Cell, 167, 397, 10.1016/j.cell.2016.08.069 Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N Engl J Med, 375, 819, 10.1056/NEJMoa1604958 Ayers, 2017, IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade, J Clin Investig, 127, 2930, 10.1172/JCI91190 Karachaliou, 2018, Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients, Ther Adv Med Oncol, 10, 10.1177/1758834017749748 Benci, 2016, Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade, Cell, 167, 1540, 10.1016/j.cell.2016.11.022 Johnson, 2009, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, 114, 535, 10.1182/blood-2009-03-211714 Tran, 2014, Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer, Science, 344, 641, 10.1126/science.1251102 Lu, 2013, Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression, J Immunol, 190, 6034, 10.4049/jimmunol.1202830 Schumacher, 2015, Neoantigens in cancer immunotherapy, Science, 348, 69, 10.1126/science.aaa4971 Gubin, 2014, Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, Nature, 515, 577, 10.1038/nature13988 van Rooij, 2013, Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma, J Clin Oncol – Off J Am Soc Clin Oncol, 31, e439, 10.1200/JCO.2012.47.7521 McGranahan, 2016, Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, 351, 1463, 10.1126/science.aaf1490 Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498 Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Goodman, 2017, Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers, Mol Cancer Ther, 16, 2598, 10.1158/1535-7163.MCT-17-0386 Dong, 2017, Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma, Clin Cancer Res, 23, 3012, 10.1158/1078-0432.CCR-16-2554 Hugo, 2016, Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma, Cell, 165, 35, 10.1016/j.cell.2016.02.065 Peng, 2016, Loss of PTEN promotes resistance to T cell-mediated immunotherapy, Cancer Discov, 6, 202, 10.1158/2159-8290.CD-15-0283 George, 2017, Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma, Immunity, 46, 197, 10.1016/j.immuni.2017.02.001 Heemskerk, 2013, The cancer antigenome, Embo j, 32, 194, 10.1038/emboj.2012.333 Robbins, 2013, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells, Nat Med, 19, 747, 10.1038/nm.3161 Balachandran, 2017, Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer, Nature, 551, 512, 10.1038/nature24462 Miao, 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma, Science, 359, 801, 10.1126/science.aan5951 Rajasagi, 2014, Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia, Blood, 124, 453, 10.1182/blood-2014-04-567933 Rooney, 2015, Molecular and genetic properties of tumors associated with local immune cytolytic activity, Cell, 160, 48, 10.1016/j.cell.2014.12.033 Schumacher, 2014, A vaccine targeting mutant IDH1 induces antitumour immunity, Nature, 512, 324, 10.1038/nature13387 Wick, 2014, Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer, Clin Cancer Res, 20, 1125, 10.1158/1078-0432.CCR-13-2147 Luksza, 2017, A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy, Nature, 551, 517, 10.1038/nature24473 Dudley, 2016, Microsatellite instability as a biomarker for PD-1 blockade, Clin Cancer Res, 22, 813, 10.1158/1078-0432.CCR-15-1678 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Llosa, 2015, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov, 5, 43, 10.1158/2159-8290.CD-14-0863 Ghoneim, 2017, De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation, Cell, 170, 142, 10.1016/j.cell.2017.06.007 Chiappinelli, 2016, Combining epigenetic and immunotherapy to combat cancer, Cancer Res, 76, 1683, 10.1158/0008-5472.CAN-15-2125 Wherry, 2015, Molecular and cellular insights into T cell exhaustion, Nat Rev Immunol, 15, 486, 10.1038/nri3862 Philip, 2017, Chromatin states define tumour-specific T cell dysfunction and reprogramming, Nature, 545, 452, 10.1038/nature22367 James, 2006, Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b, Oncogene, 25, 6975, 10.1038/sj.onc.1209678 Roulois, 2015, DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts, Cell, 162, 961, 10.1016/j.cell.2015.07.056 DuPage, 2015, The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation, Immunity, 42, 227, 10.1016/j.immuni.2015.01.007 Dobenecker, 2018, Signaling function of PRC2 is essential for TCR-driven T cell responses, J Exp Med, 215, 1101, 10.1084/jem.20170084 Yin, 2015, Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity, Proc Natl Acad Sci U S A, 112, 15988, 10.1073/pnas.1521740112 Peng, 2015, Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy, Nature, 527, 249, 10.1038/nature15520 Nagarsheth, 2016, PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer, Cancer Res, 76, 275, 10.1158/0008-5472.CAN-15-1938 Wang, 2018, Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity, Cell Rep, 23, 3262, 10.1016/j.celrep.2018.05.050 Goswami, 2018, Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy, J Clin Investig, 128, 3813, 10.1172/JCI99760 Zingg, 2017, The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy, Cell Rep, 20, 854, 10.1016/j.celrep.2017.07.007 Whittaker, 2010, Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma, J Clin Oncol : Off J Am Soc Clin Oncol, 28, 4485, 10.1200/JCO.2010.28.9066 Briere, 2018, The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy, Cancer Immunol Immunother, 67, 381, 10.1007/s00262-017-2091-y Woods, 2015, HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade, Canc Immunol Res, 3, 1375, 10.1158/2326-6066.CIR-15-0077-T Cabel, 2017, Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study, Ann Oncol, 28, 1996, 10.1093/annonc/mdx212 Khagi, 2017, Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy, Clin Cancer Res, 23, 5729, 10.1158/1078-0432.CCR-17-1439 Gandara, 2018, Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, Nat Med, 24, 1441, 10.1038/s41591-018-0134-3 Wang, 2019, Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel, JAMA Oncol, 5, 696, 10.1001/jamaoncol.2018.7098 Saenger, 2014, Blood mRNA expression profiling predicts survival in patients treated with tremelimumab, Clin Cancer Res, 20, 3310, 10.1158/1078-0432.CCR-13-2906 Yuan, 2014, Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab, Canc Immunol Res, 2, 127, 10.1158/2326-6066.CIR-13-0163 Takeuchi, 2018, Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma, Int Immunol, 30, 13, 10.1093/intimm/dxx073 Nonomura, 2016, Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients, Oncoimmunology, 5, 10.1080/2162402X.2016.1248327 Gros, 2016, Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients, Nat Med, 22, 433, 10.1038/nm.4051 Kamphorst, 2017, Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients, Proc Natl Acad Sci U S A, 114, 4993, 10.1073/pnas.1705327114 Gibney, 2015, Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma, Clin Cancer Res, 21, 712, 10.1158/1078-0432.CCR-14-2468 Weber, 2016, Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab, Canc Immunol Res, 4, 345, 10.1158/2326-6066.CIR-15-0193 Krieg, 2018, High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy, Nat Med, 24, 144, 10.1038/nm.4466 Routy, 2018, The gut microbiota influences anticancer immunosurveillance and general health, Nat Rev Clin Oncol, 15, 382, 10.1038/s41571-018-0006-2 Kawamoto, 2012, The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut, Science, 336, 485, 10.1126/science.1217718 Sivan, 2015, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, 350, 1084, 10.1126/science.aac4255 Vetizou, 2015, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota, Science, 350, 1079, 10.1126/science.aad1329 Gopalakrishnan, 2018, Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, 359, 97, 10.1126/science.aan4236 Matson, 2018, The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients, Science, 359, 104, 10.1126/science.aao3290 Routy, 2018, Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science, 359, 91, 10.1126/science.aan3706 Mkrtichyan, 2011, Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms, Eur J Immunol, 41, 2977, 10.1002/eji.201141639 Longo, 2019, Strategies to improve cancer immune checkpoint inhibitors efficacy, other than abscopal effect: a systematic review, Cancers (Basel), 11, 10.3390/cancers11040539 Emens, 2015, The interplay of immunotherapy and chemotherapy: harnessing potential synergies, Canc Immunol Res, 3, 436, 10.1158/2326-6066.CIR-15-0064 Goel, 2017, CDK4/6 inhibition triggers anti-tumour immunity, Nature, 548, 471, 10.1038/nature23465 Zhang, 2018, Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance, Nature, 553, 91, 10.1038/nature25015 Homet Moreno, 2016, Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma, Oncoimmunology, 5, 10.1080/2162402X.2015.1052212 Ribas, 2014, Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study, Lancet Oncol, 15, 954, 10.1016/S1470-2045(14)70301-8 Reilley, 2017, Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies, J Immunother Cancer, 5, 35, 10.1186/s40425-017-0238-1 Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309 Chi, 2012, Regulation and function of mTOR signalling in T cell fate decisions, Nat Rev Immunol, 12, 325, 10.1038/nri3198 Shen, 2019, Metabolic regulation of TH17 cells, Mol Immunol, 109, 81, 10.1016/j.molimm.2019.03.005 Ahmad, 2017, Differential PI3Kdelta signaling in CD4(+) T-cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy, Cancer Res, 77, 1892, 10.1158/0008-5472.CAN-16-1839 Allard, 2013, Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs, Clin Cancer Res, 19, 5626, 10.1158/1078-0432.CCR-13-0545 Hong, 2015, beta-catenin promotes regulatory T-cell responses in tumors by inducing vitamin A metabolism in dendritic cells, Cancer Res, 75, 656, 10.1158/0008-5472.CAN-14-2377 Sethumadhavan, 2017, Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells, PLoS One, 12, 10.1371/journal.pone.0187314 Noman, 2014, PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation, J Exp Med, 211, 781, 10.1084/jem.20131916 Bindra, 2007, Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia, Oncogene, 26, 2048, 10.1038/sj.onc.1210001 Meng, 2005, Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells, Radiother Oncol, 76, 168, 10.1016/j.radonc.2005.06.025 Reits, 2006, Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy, J Exp Med, 203, 1259, 10.1084/jem.20052494 Demaria, 2016, Radiotherapy: changing the game in immunotherapy, Trends Canc, 2, 286, 10.1016/j.trecan.2016.05.002 Dovedi, 2017, Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade, Clin Cancer Res, 23, 5514, 10.1158/1078-0432.CCR-16-1673 Klug, 2013, Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy, Cancer Cell, 24, 589, 10.1016/j.ccr.2013.09.014 Canter, 2017, Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial, J Immunother Cancer, 5, 98, 10.1186/s40425-017-0305-7 Shen, 2017, Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway, Oncotarget, 8, 80506, 10.18632/oncotarget.19193 Muroyama, 2017, Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment, Canc Immunol Res, 5, 992, 10.1158/2326-6066.CIR-17-0040 Shahabi, 2015, Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy, Am J Clin Oncol, 38, 90, 10.1097/COC.0b013e3182868ec8 Twyman-Saint Victor, 2015, Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer, Nature, 520, 373, 10.1038/nature14292 Tang, 2017, Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells, Clin Cancer Res, 23, 1388, 10.1158/1078-0432.CCR-16-1432 Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937 Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N Engl J Med, 379, 2342, 10.1056/NEJMoa1809697 Luke, 2018, Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors, J Clin Oncol – Off J Am Soc Clin Oncol, 36, 1611, 10.1200/JCO.2017.76.2229 Hiniker, 2016, A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma, Int J Radiat Oncol Biol Phys, 96, 578, 10.1016/j.ijrobp.2016.07.005 Postow, 2012, Immunologic correlates of the abscopal effect in a patient with melanoma, N Engl J Med, 366, 925, 10.1056/NEJMoa1112824 Yu, 2009, The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells, Nat Immunol, 10, 48, 10.1038/ni.1674 Melero, 2015, Evolving synergistic combinations of targeted immunotherapies to combat cancer, Nat Rev Canc, 15, 457, 10.1038/nrc3973 Anderson, 2016, Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation, Immunity, 44, 989, 10.1016/j.immuni.2016.05.001 Zamarin, 2017, Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity, Nat Commun, 8, 14340, 10.1038/ncomms14340 Ribas, 2017, Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy, Cell, 170, 1109, 10.1016/j.cell.2017.08.027 Zacharakis, 2018, Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer, Nat Med, 24, 724, 10.1038/s41591-018-0040-8 Maute, 2015, Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging, Proc Natl Acad Sci U S A, 112, E6506, 10.1073/pnas.1519623112 Pedicord, 2011, Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance, Proc Natl Acad Sci U S A, 108, 266, 10.1073/pnas.1016791108